ArticleClinical and translational science2022

The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.

Alexander P J Vlaar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.